SCHEMBL6440776

SCHEMBL6440776

COC(=O)c1ccc(C(=O)Nc2ccccc2Nc2ccc(OC)cc2)s1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
F10 P00742 1/20 0.52
MAPT P10636 4/20 0.51
ALOX12 P18054 1/20 0.51
MAPK1 P28482 1/20 0.51
HSD17B10 Q99714 1/20 0.51
SMN1; SMN2 Q16637 5/20 0.51
KDM4E B2RXH2 3/20 0.51
LMNA P02545 1/20 0.51
RAB9A P51151 6/20 0.47
NPC1 O15118 4/20 0.47
TP53 P04637 1/20 0.47
ALDH1A1 P00352 3/20 0.45
GAA P10253 2/20 0.45
THRB P10828 1/20 0.45
HTT P42858 1/20 0.45
RECQL P46063 1/20 0.45
MMP14 P50281 1/20 0.45
TDP1 Q9NUW8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6439783 0.81 F10 (0.73) MEN1KMT2AF10MAPTALOX12
SCHEMBL6438706 0.80 F10 (0.82) MEN1KMT2AF10MAPTALOX12
SCHEMBL7752677 0.76 F10 (0.79) MEN1KMT2AF10MAPTALOX12
SCHEMBL14009330 0.75 MEN1 (0.52) MEN1KMT2AF10SMN1; SMN2KDM4E
SCHEMBL3791523 0.74 SMN1; SMN2 (0.47) MEN1KMT2AMAPK1SMN1; SMN2KDM4E
SCHEMBL1921461 0.74 RAB9A (0.72) MEN1KMT2AMAPTALOX12MAPK1
SCHEMBL10896784 0.72 KMT2A (0.59) MEN1KMT2AF10MAPTALOX12
SCHEMBL11299833 0.72 MEN1 (0.59) MEN1KMT2AF10MAPTALOX12
SCHEMBL11306206 0.72 TGM2 (0.68) MEN1KMT2AF10MAPTALOX12
SCHEMBL11306733 0.71 MEN1 (0.57) MEN1KMT2AF10MAPTALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1517897-A2 BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ESTROGEN AGONISTS/ANTAGONISTS Pfizer Products Inc. (US) 2005-03-30 EP disclosed
US-20040002524-A1 Benzimidazole compounds and their use as estrogen agonists/antagonists CHESWORTH RICHARD (US) 2004-01-01 US disclosed
WO-2004000817-A2 BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ESTROGEN AGONISTS/ANTAGONISTS PFIZER PRODUCTS INC. (US) 2003-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002524-A1 Benzimidazole compounds and their use as estrogen agonists/antagonists ESR1, GPER1, ESR2 MEN1 4482/4885KMT2A 1738/4885F10 4492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.